Changes in Body Composition After EPA Supplementation in Head and Neck Patients

Inclusion Criteria: * \- Age between 18 and 75 years inclusive. * A performance status 0-1 according to ECOG (Eastern Cooperative Oncology Group) scale at the time of inclusion in the study. * Expectancy greater than 3 months life. * Location: oral cavity, oropharynx, larynx,hypopharynx, nasopharynx and sinuses. * Patients with squamous cell carcinoma of the head and neck classified as locally advanced (Stage III, IVa-IVb). * Patients with medical conditions to receive neoadjuvant chemotherapy (CT) induction followed by radiotherapy (RDT) normo fraction combined with QT or biological. * Neutrophil ≥1500 / mm3, platelet count ≥150,000 / mm3 and hemoglobin ≥10g / dL. * Adequate liver function: total bilirubin ≤ 1 x ULN; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN; Alkaline phosphatase (ALP) ≤ 5 x ULN. * Serum albumin-adjusted calcium ≤ 1.25 x upper limit of normal (ULN). * Using an effective contraceptive method for patients of both sexes where the risk of conception and / or pregnancy. * Signature of written informed consent before any study-specific procedures Exclusion Criteria: * \- Metastatic disease (stage IVc). * Surgery, radiotherapy and / or chemotherapy prior to study disease treatment. * T3 N0-1 larynx. * Other stadiums than III or IV without distant metastases and stable disease. * Another synchronous squamous carcinoma. * Diagnosis of other malignancy within the past 5 years, except in situ of the cervix and / or adequately treated basal cell carcinoma skin cancer. * Active infection (infection requiring intravenous antibiotic), including active tuberculosis and HIV diagnosed. * Uncontrolled hypertension defined as systolic blood pressure ≥180mm Hg and / or diastolic blood pressure≥ 130 mm Hg at rest. * Pregnancy (absence must be confirmed with β-HCG (Human chorionic gonadotropin) serum test) or lactating. * Systemic, chronic immune and concomitant treatment, or hormonal treatment of cancer. * Other concomitant antineoplastic treatment. * Clinically significant coronary artery or a history of myocardial infarction in the last 12 months or high risk of uncontrolled arrhythmia or uncontrolled heart failure. * Chronic obstructive pulmonary disease that would have required ≥3 hospitalizations in the last 12 months. * Uncontrolled active peptic ulcer. * Presence of a psychological or medical illness that prevented the study by the patient or to grant the signature on the informed consent. * Abuse of known drugs (with the exception of heavy drinking). * Allergic reaction known against any component of study treatment. * Previous treatment with monoclonal antibodies or other inhibitors of signal transduction or treatment directed against the EGFR (epidermal growth factor receptor). * Any experimental therapy within 30 days prior to study entry.